Brilique 90 mg 56 tablets

Tradename:

Brilique

Composition:

Each tablet contains:

Ticagrelor 90 mg.

Auxiliary components:

mannitol, calcium hydrogen phosphate, sodium carboxymethyl starch, hyprolose, magnesium stearate.

Properties:

Brilik@ contains ticagrelor, a member of the chemical class of cyclopentyltriazolopyrimidines, which is a selective and reversible direct acting P2Y12 receptor antagonist and prevents ADPmediated P2Y12-dependent platelet activation and aggregation. Ticagrelor does not prevent ADP binding, but its interaction with the platelet P2Y12 receptor prevents ADP-induced signal transduction. Because Platelets are involved in the initiation and / or developme of thrombotic complications of atherosclerosis, and inhibition of platelet function has been shown to reduce the risk of cardiovascular events such as death, myocardial infarction, or stroke.

Adenosine is formed locally in places of hypoxia and tissue damage by release from ATP and ADP. Ticagrelor inhibits ENT-I and prolongs Tl / 2 of adenosine, thereby increasing its local extracellular concentration, enhancing the local adenosine response. Ticagrelor has no clinically significant direct effect on adenosine receptors (Al, A2A, A2B, A3) and is not metabolized to adenosine. Adenosine has the following effects, which include: vasodilation, cardioprotection, inhibition of platelet aggregation, modulation of inflammation, and dyspnea, which can affect the clinical profile of ticagrelor. In healthy volunteers and in patients with acute coronar syndrome (ACS), ticagrelor has been show enhance the following effects of adenosine: vasodilation (assessed as increased coronary

blood flow in healthy volunteers; headache), inhibition of platelet function (in vitro in whole human blood), and dyspnea. However, the association of increased local concentrations of adenosine with clinical outcomes (morbidity and mortality) has not been proven.

Indications:

In combination with acetylsalicylic acid:

– for the prevention of atherothrombotic complications in patients with acute coronary syndrome (unstable angina pectoris, myocardial infarction without ST segment elevation or myocardial infarction with ST segment elevation [STEMI]), including patients who received drug therapy and patients undergoing percutaneous coronary intervention or coronary artery bypass surgery

Method of administration and dosage:

Take the drug after consulting a doctor.

Initial dose:

2 tablets (180mq) per dav, at the same time.

After taking 1 tablet 2 times a day. The course of treatment is 12 months.

Take at the same time in the morning and in the evening.

Contraindications:

hypersensitivity to ticagrelor or any component of the drug;

• active pathological bleeding;
• history of intracranial hemorrhage;
• moderate or severe hepatic impairment;

-the concomitant use of ticagrelor with potent inhibitors of CYP3A4 (for example, ketoconazole, clarithromycin, nefazodone, ritonavir and atazanavir);

-Children and adolescence up to 18 years (due to the lack of data on the effectiveness and safety of use in this group of patients).

Precautions:

In patients with acute coronary syndrome treated with Brilik@ and acetylsalicylic acid, there was an increased risk of major bleeding and bleeding not associated with CABG and requiring increased medical attention, such as major + minor bleeding as defined by PLATO, but the risk of fatal / threatening life of bleeding.

When prescribing Briliku @, the ratio of the benefits of preventing atherothrombotic events and the risk in patients with an increased likelihood of bleeding should be assessed.

Side effects:

Nervous system, psyche and sensory organs: confusion, dizziness, fainting, headache, intracranial hemorrhage, anxiety, insomnia.

Cardiovascular system, blood (hemostasis, hematopoiesis) and lymphatic system: arterial hypotension, tachycardia, arterial hypertension, bradycardia, chest pain, heart rhythm disturbances.

Digestive system: gastrointestinal bleeding (including bleeding from the gums, rectal bleeding, bleeding from a stomach ulcer),

diarrhea, nausea, dyspepsia, constipation.

Storage method:

At a temperature not higher than 30 degrees. In a dry place.

Packaging:

The cardboard box holds 60 and 180 tablets, paper instructions.